Active Ingredient History

  • Now
Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors. Marketed under the brand name BYSTOLIC, Nebivolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.   NCATS

  • SMILES: OC(CNCC(O)C1CCc2cc(F)ccc2O1)C3CCc4cc(F)ccc4O3
  • Mol. Mass: 405.44
  • ALogP: 2.36
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)


$0.4386 - $1.2374

United States

$3.5260 - $45.1210
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

1,1'-[bis(6-fluoro-3,4-dihydro-2h-1-benzopyran-2-yl)]-2,2'-iminodiethanol | 1,1'-bis(6-fluoro-3,4-dihydro-2h-1-benzopyran-2-yl)-2,2'-iminodiethanol | alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2h-1-benzopyran-2-methanol) | alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol) | bystolic | hypoloc | narbivolol | nebilet | nebivolol | nebivolol hcl | nebivolol hydrochloride | nebivololum | r-65824 | ro-67555 | vasoxen


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue